0.76
-0.017(-2.18%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.77 |
| Day High | 0.8 |
| Day Low | 0.76 |
| 52-Week High | 2.26 |
| 52-Week Low | 0.45 |
| Volume | 111,540 |
| Average Volume | 207,311 |
| Market Cap | 57.42M |
| PE | -1.06 |
| EPS | -0.72 |
| Moving Average 50 Days | 1.04 |
| Moving Average 200 Days | 1.05 |
| Change | -0.02 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $65.52 as of April 20, 2025 at a share price of $0.762. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $35.44 as of April 20, 2025 at a share price of $0.762.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire Inc.
Apr 15, 2025 2:23 AM GMT
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma Announces Proposed Public Offering
GlobeNewswire Inc.
Apr 14, 2025 9:05 PM GMT
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma to Host Business Update Call and Webcast
GlobeNewswire Inc.
Apr 14, 2025 9:02 PM GMT
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Data not available